...
首页> 外文期刊>Internal medicine. >Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma
【24h】

Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma

机译:成年T细胞白血病/淋巴瘤患者接受Mogamulizumab治疗期间的腹水保留

获取原文
           

摘要

A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.
机译:一名患有难治性成人T细胞白血病/淋巴瘤(ATLL)的74岁女性接受了三个疗程的莫加莫珠单抗治疗。尽管获得了完全缓解,但此后她仍表现出进行性腹水。腹水分析和实验室检查未发现ATLL侵袭,传染病或肝硬化的证据。腹水中莫加莫珠单抗的浓度维持在血浆中的约10-15%。 Mogamulizumab被认为是其腹水的合理发病机理。据我们所知,这是第一个提示莫加莫珠单抗诱发腹水的报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号